December 1, 1986Angiology
Arrhythmia Control by Selective Lengthening of Cardiac Repolarization: Role of N-Acetylprocainamide, Active Metabolite of Procainamide
Key result
NAPA shows potential to suppress ventricular and atrial arrhythmias by selectively lengthening cardiac repolarization.
Why the study?
Selective lengthening of cardiac repolarization with increased effective refractory period represents a distinct antiarrhythmic mechanism exemplified by N-acetylprocainamide (NAPA).
Does N-Acetylprocainamide (NAPA) improve arrhythmia control in patients with heart disease?
Comparison
N-acetylprocainamide (NAPA) effects on repolarization versus parent compound procainamide
Design
Review of electrophysiologic and clinical data
Authors
Discussion
Loading...
Member takes
Implication
Does not support routine use; leaves open NAPA's role in arrhythmia management pending randomized trials.
Structured PICO
Does N-Acetylprocainamide (NAPA) improve arrhythmia control in patients with heart disease?
P
Population
Patients with heart disease experiencing arrhythmias (premature ventricular contractions, ventricular tachycardia, atrial flutter, and atrial fibrillation)
I
Intervention
N-Acetylprocainamide (NAPA)
O
Outcome
Arrhythmia control (suppression of premature ventricular contractions, prevention of ventricular tachycardia, reversal of atrial flutter and fibrillation)
N-Acetylprocainamide (NAPA) is a pharmacologically active metabolite of procainamide with distinct Class III antiarrhythmic properties that warrants further clinical evaluation for arrhythmia management.
Cite This Study
Singh et al. (1986) conducted a review in Arrhythmia. N-Acetylprocainamide (NAPA) was evaluated. N-Acetylprocainamide (NAPA) acts as a Class III antiarrhythmic agent by selectively lengthening cardiac repolarization, showing potential to suppress ventricular and atrial arrhythmias.